Genadyne Biotechnologies
Private Company
Total funding raised: $15M
Overview
Genadyne Biotechnologies is a privately held, commercial-stage medical device company focused on the wound care and medical device sectors. Its core business revolves around its NPWT systems (marketed under brands like XLR8, UNO, and DUO) and a portfolio of advanced wound dressings, including its signature 'Green Foam.' The company emphasizes US manufacturing, global distribution, and compliance with major international quality standards like ISO 13485 and MDSAP. With over two decades of operation, Genadyne is an established player in the advanced wound care market, aiming to provide cost-effective solutions that improve clinical efficiency and patient quality of life.
Technology Platform
Negative Pressure Wound Therapy (NPWT) systems and a proprietary portfolio of advanced wound dressings, including Green Foam, PVA Foam, and silicone-based dressings, supported by multi-patient and single-patient pump systems with features like instillation therapy.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Genadyne operates in the highly competitive advanced wound care market, competing directly with major players like 3M (KCI), Smith & Nephew, Cardinal Health, and Molnlycke, who have broader portfolios and greater sales resources. Its strategy focuses on competing through cost-effectiveness, a full product portfolio, and US-based manufacturing quality, targeting specific segments and geographies where these factors are prioritized.